We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New 1-Minute COVID-19 Antibody Test Uses Innovative Flow-Through Technology to Deliver Results

By LabMedica International staff writers
Posted on 16 Oct 2020
A new one-minute antibody test for COVID-19 launched in Europe is the only test of its kind to use innovative flow-through technology to deliver results, making it far faster than other antibody tests currently available.

bioLytical Laboratories (Vancouver, BC, Canada) has launched INSTI COVID-19 Antibody Test, its new one-minute test that detects antibodies to SARS-CoV-2 with high accuracy, in Europe following the notification of CE mark and approval to sell the test across the region. More...
The test detects total antibodies to SARS-CoV-2 and is the only one of its kind to use innovative flow-through technology to deliver results, making it far faster than other antibody tests currently available. The INSTI COVID-19 Antibody Test is completely portable, does not require additional equipment and can be performed in a multitude of settings with easy-to-interpret results. Test providers have the advantage of running more tests in less time, due to INSTI's market-leading speed.

“Reliable and truly rapid antibody tests are an important part of our response to this global crisis,” said Robert Mackie, Chief Executive Officer. “The INSTI COVID-19 Antibody Test is a uniquely effective tool and distribution of our one-minute test kits around the globe is a critical step for tackling the spread of this virus.”

Related Links:
bioLytical Laboratories


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Urine Analyzer
respons® UDS100
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.